| 000 | 01468 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250511181108.0 | ||
| 264 | 0 | _c19920521 | |
| 008 | 199205s 0 0 eng d | ||
| 022 | _a0300-0664 | ||
| 024 | 7 |
_a10.1111/j.1365-2265.1992.tb01441.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMullis, P E | |
| 245 | 0 | 0 |
_aHalf-life of exogenous growth hormone following suppression of endogenous growth hormone secretion with somatostatin in type I (insulin-dependent) diabetes mellitus. _h[electronic resource] |
| 260 |
_bClinical endocrinology _cMar 1992 |
||
| 300 |
_a255-63 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aDepression, Chemical |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 1 _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGlucose Clamp Technique |
| 650 | 0 | 4 |
_aGrowth Hormone _xblood |
| 650 | 0 | 4 | _aHalf-Life |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aSomatostatin _xpharmacology |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aPal, B R | |
| 700 | 1 | _aMatthews, D R | |
| 700 | 1 | _aHindmarsh, P C | |
| 700 | 1 | _aPhillips, P E | |
| 700 | 1 | _aDunger, D B | |
| 773 | 0 |
_tClinical endocrinology _gvol. 36 _gno. 3 _gp. 255-63 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2265.1992.tb01441.x _zAvailable from publisher's website |
| 999 |
_c1355164 _d1355164 |
||